Patients with posttraumatic stress disorder exhibit an altered phenotype of regulatory T cells by Mladen Jergović et al.
ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
Jergović et al. Allergy, Asthma & Clinical Immunology 2014, 10:43
http://www.aacijournal.com/content/10/1/43RESEARCH Open AccessPatients with posttraumatic stress disorder exhibit
an altered phenotype of regulatory T cells
Mladen Jergović1,5*, Krešo Bendelja1, Anđelko Vidović2, Ana Savić1, Valerija Vojvoda1, Neda Aberle3, Sabina Rabatić5,
Tanja Jovanovic4 and Ante Sabioncello5Abstract
Background: Regulatory T cells (Tregs) play a key role in immune homeostasis in vivo. Tregs have a critical role in
preventing the development of autoimmune diseases and defects in Treg function are implicated in various
autoimmune disorders. Individuals with posttraumatic stress disorder (PTSD) have higher prevalence of autoimmune
disorders than the general population. We hypothesized that war veterans with PTSD would exhibit a decreased
number and/or altered phenotype of Tregs.
Methods: We analyzed peripheral blood mononuclear cells (PBMCs) of patients with PTSD (N = 21) (mean age = 45.9)
and age-matched healthy controls (N = 23) (mean age = 45.7) to determine the proportion of Tregs and their
phenotype according to the expression of CD127 and HLA-DR markers which describe the differentiation
stages of Tregs. In addition, we analyzed the expression of membrane ectoenzyme CD39 on Tregs of the
study groups, an important component of the suppressive machinery of Tregs.
Results: We found no differences in the proportion of Tregs between PTSD patients and controls, but PTSD
patients had a higher percentage of CD127−HLA-DR− Tregs and a lower percentage of CD127loHLA-DR+ Tregs
compared to controls. There was no difference in expression of CD39 on Tregs of the study groups.
Conclusions: Although the proportions of Tregs in PTSD patients were unchanged, we found that they
exhibit a different phenotype of Tregs that might be less suppressive. Impaired differentiation and function of
Tregs is likely involved in disruption of immune homeostasis in PTSD.
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Regulatory T cells (Tregs) play a major role in maintain-
ing homeostasis of the immune system by restraining
the activity of effector cells and auto-reactive T lympho-
cytes, thus controlling immune reactivity. Tregs were first
described in 1995 as a subset of CD4+ T cells expressing
high levels of the interleukin (IL)-2 receptor alpha-chain
(CD25) whose depletion led to development of auto-
immune diseases [1]. Since CD25 is also expressed by
antigen experienced and recently activated effector T cells,
identification of transcription factor forkhead box P3
(FOXP3) as a specific intracellular marker of Tregs, has* Correspondence: mjergovi@unizg.hr
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unless otherwise stated.vastly improved the identification of this subpopulation of
T cells [2,3]. X-chromosome encoded transcription factor
FOXP3 is necessary for the development and function of
Tregs and humans with mutation leading to loss of func-
tion in the FOXP3 gene develop a fatal lymphoprolifera-
tive autoimmune disorder, IPEX (immune dysregulation,
polyendocrinopathy, enteropathy, X-linked) [4,5]. Al-
though expressed predominantly by Tregs, FOXP3 is not
an exclusive marker of Tregs [6] as it is induced during
T-cell receptor (TCR) stimulation in conventional CD4+
T cells. Other markers such as low levels or lack of expres-
sion of IL-7 receptor CD127 have been suggested as useful
in identifying peripheral Tregs [7].
Human T cells with regulatory function contain other
FOXP3− subpopulations (Th3, Tr1, iTr35, and CD8+CD28−)
but CD4+CD25hiFOXP3+ are the most studied and com-
prehended in the context of homeostasis and autoimmunityl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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immune diseases such as rheumatoid arthritis, multiple
sclerosis and psoriasis yielded conflicting results with sys-
temic lupus erythematosus being the only autoimmune
disease showing a consistent decrease of Tregs in the per-
iphery [9]. However functional defects of Tregs have been
observed in different human autoimmune diseases [10].
Expression of some surface receptors discriminates be-
tween functionally distinct Treg populations. HLA-DR is
expressed on terminally differentiated Tregs which are
more suppressive than the HLA-DR− subset [11]. CD127
discriminates between human regulatory and activated
T cells [12] and frequency of CD127 expressing cells
within the FOXP3+ population correlates with poor Treg
function [13]. CD39 is an ectoenzyme that degrades ad-
enosine triphosphate (ATP) to adenosine monophosphate
(AMP). It is expressed by some Tregs and conveys sup-
pression by hydrolyzing extracellular ATP released by
damaged cells [14]. CD39+ Tregs have the capability of
suppressing IL-17 production and are impaired in mul-
tiple sclerosis [15].
Posttraumatic stress disorder (PTSD) is a trauma-
related disorder that may develop after exposure to one
or more traumatic events [16] and is characterized by
recurring flashbacks, avoidance of memories of the
event, emotional numbing, and hyperarousal. It is esti-
mated that lifetime prevalence of PTSD in the general
population is 6.8–8% [17,18] but combat veterans or in-
dividuals exposed to war have a higher risk of developing
PTSD with reported prevalence rates ranging between
1.4% and 31% [19]. PTSD is associated with various bio-
logical and behavioral changes that constitute a higher
risk for developing somatic illness [20] and higher mor-
tality rates, especially from heart disease [21]. Several
autoimmune or inflammatory disorders have been linked
to PTSD, most notably rheumatoid arthritis [22], psoria-
sis and thyroid disease [23].
Studies of the immune system in PTSD have yielded con-
flicting results, with increased levels of pro-inflammatory
cytokines (IL-1β, IL-6 and tumor necrosis factor (TNF)-α),
lower total T cells counts, and increased reactivity to anti-
gen skin tests being the most consistent findings [24,25].
Only one study has investigated Tregs in PTSD [26] find-
ing decreased number of Tregs in blood of PTSD patients.
Another study [27] showed a decreased number of Tregs
in the peripheral blood of human subjects after an acute
laboratory stressor. Studies in mice showed that chronic
psychosocial stress induced a reduction of regulatory
T cells in peripheral lymph nodes, accompanied by in-
creased T cell effector functions [28].
We hypothesized that war veterans with PTSD would
exhibit a decreased number and/or altered phenotype of
Tregs. In addition to determining percentages of total
Tregs (CD3+CD4+CD25+FOXP3+) in peripheral blood ofPTSD patients, we further characterized Tregs according
to their expression of HLA-DR, CD127 and CD39 to in-
vestigate whether PTSD patients exhibit a different pheno-




PTSD patients (n = 25) were Croatian male combat vet-
erans, recruited among outpatients at General hospital
“dr. Josip Benčević”, Slavonski Brod, Croatia who volun-
teered to participate in the study. All patients met the
ICD-10 [29] PTSD criteria, the official classification in
Croatian psychiatric practice. Healthy controls (n = 25)
were men matched for age and demographics. The study
was approved by the Ethic Committee of the hospital and
written informed consent was obtained from all subjects.
Prior to phlebotomy, all study participants were exam-
ined by an experienced clinician (a psychiatrist), and med-
ical history data relevant to the purpose of this study were
recorded. The subjects were then asked to complete rating
scales for PTSD, depression and anxiety symptoms.
The level of PTSD symptoms was assessed with the Los
Angeles Symptom Checklist (LASC) [30] a self-report
measure of PTSD and associated features. We used the
43-item version of the LASC to assess PTSD. Respondents
rated the extent to which specific symptoms were a prob-
lem for them, using a 5-point scale ranging from 0 (no
problem) to 4 (extreme problem). The diagnosis of PTSD
was confirmed in all patients, i.e. out of 17 diagnostic
items they reported (with a rating of four) at least one
item assessing reexperiencing of the trauma, three items
indexing avoidance and numbing, and two items reflect-
ing increased arousal. Depression symptoms were assessed
with the Beck Depression Inventory (BDI) [31] and current
anxiety level (state anxiety) was determined by the corre-
sponding part of Spielberger State-Trait Anxiety Inventory
(STAI) [32].
Healthy controls did not meet lifetime or current cri-
teria for any psychiatric disorder and had no symptoms
or signs of current psychiatric disease. Due to ethical
considerations the PTSD patients did not discontinue
their regular medications. Standard laboratory tests were
also performed in all participants. Two PTSD patients
were excluded from the analysis because of high levels
of CRP (>10 mg/L) indicating acute inflammation or
infection. Another two PTSD patient were excluded
because of chronic illness (multiple sclerosis and dia-
betes) and two controls were excluded due to very
young age (more than 20 years below the group aver-
age). At the time of sampling, all other study subjects
had no symptoms or signs of acute or chronic phys-
ical illness. None of the included participants reported
intake of glucocorticoids.
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tients (n = 17) were medicated at the time of the study.
They were taking selective serotonin reuptake inhibitors
(SSRIs) (n = 12), benzodiazepines (n = 15), or antipsychotics
(as an augmentation therapy, n = 8).
Blood sampling and lymphocyte phenotyping
We collected fasting whole blood by venipuncture from
25 PTSD patients and 25 healthy controls on the same
day between 7 and 9 AM. Blood was collected in sodium
heparin treated tubes and serum tubes (BD Biosciences,
Heidelberg, Germany). Serum tubes were sent to the hos-
pital laboratory for measurement of C-reactive protein
(CRP) levels to test for the presence of acute inflamma-
tion. Determination of CRP was performed using a stand-
ard latex immunoassay; CRP Vario (Abbott Diagnostics,
Lake Forest, USA). Absolute numbers of lymphocytes
were determined from whole blood using TruCOUNT™
Tubes (BD Biosciences). 50 μL of whole blood was incu-
bated for 15 minutes with fluorescein isothiocyanate
(FITC)-conjugated anti-CD45 (clone 2D1) and phycoeryth-
rin (PE)-conjugated anti-CD14 (MφP9) (BD Biosciences)
antibodies at room temperature, then treated with 450 μl
of lysing buffer (BD Biosciences) for 10 minutes before
flow cytometry was performed.
Peripheral blood mononouclear cells (PBMCs) were
isolated on Ficoll-Paque™ gradient (GE Healthcare Life
Sciences, Uppsala, Sweden). Upon separation, mono-
nuclear cells were washed, resuspended in freezing
medium (10% FCS, 10% DMSO, 80% RPMI 1640) and
transferred within a Freezing Container (Sigma-Aldrich,
St. Louis, USA) to −80°C overnight, then stored in liquid
nitrogen until further processing.. However, this was not
a concern, since T cell subpopulations have been shown to
be well preserved by cryopreservation [33]. Reports of
cryopreservation effect on FOXP3 expression are conflict-
ing, but the latest report indicates no effect if a medium
with a low concentration of FCS is used [34]. We have
tested the impact of the cryopreservation method by meas-
uring Treg frequencies and phenotype in fresh and freeze/
thawed PBMCs of a small random sample (N = 5). Frozen
PBMCs were later quickly thawed in water bath at 37°C,
resuspended in a pre-warmed RPMI 1640 medium and
stained with antibodies for phenotypic analysis. For
quantification of lymphocyte phenotypes, 500,000 cells
were stained with Alexa Fluor® 647 (AF 647)-conjugated
anti-CD3 (HIT3a), Alexa Fluor® 488 (AF 488)-conjugated
anti-CD56 (HCD56), AF 488-conjugated anti-CD16 (3G8),
PE-conjugated anti-CD19 (HIB19), peridinin-chlorophyll-
protein (PerCP)-conjugated anti-CD8a (HIT8a), and
Pacific Blue™ (PB)-conjugated anti-CD4 (RPA.T4) (Biolegend,
San Diego, USA). Following antibody staining, samples
were washed in a staining buffer and at least 20,000 cells
were collected in the lymphocyte gate. Matching isotypecontrols were used for setting positivity gates: AF 647-
conjugated mouse IgG2a, AF 488-conjugated mouse IgG1
kappa, PE-conjugated mouse IgG1 kappa, PerCP-conjugated
mouse IgG1 kappa, PB-conjugated mouse IgG1 kappa
(Biolegend).
For quantification and phenotyping of Tregs 500,000
cells were stained with PB-conjugated anti-CD4, FITC-
conjugated anti-CD25 (BC96), allophycocyanin (APC)/
cyanine 7 (Cy7)-conjugated anti-CD3(HIT3a), PerCP-
conjugated anti-HLA-DR (L243), AF 647-conjugated anti-
CD127 (HCD127) (Biolegend) and PE-CY7-conjugated
anti-CD39 (Ebioscience, San Diego, USA). After incuba-
tion in the dark for 15 minutes, cells were washed and
fixed. The cells were then washed in a permeabilization
buffer and stained with PE anti-human FOXP3 Staining
Set (Ebioscience) following manufacturer instructions.
Following antibody staining, samples were washed in the
permeabilization buffer and at least 50,000 cells in the
lymphocyte gate were collected. The isotype controls used
for setting positivity gates were as follows: PB-conjugated
mouse IgG1 kappa, FITC-conjugated mouse IgG1, kappa,
APC/Cy7-conjugated mouse IgG2a kappa, PerCP-conjugated
mouse IgG2a kappa, AF-conjugated 647 mouse IgG1
kappa (Biolegend) and PE-CY7-conjugated mouse IgG 1
kappa (Ebioscience). The gating strategy we used for iden-
tification and phenotypic characterization of Tregs is
depicted in Figure 1. All samples were run on an LSRII
flow cytometer (BD Biosciences) and data were analyzed
with FlowJo software (Tree Star, Ashland, USA).
Statistical analyses
Participants’ demographic characteristics with categorical
data were compared using Fisher exact test for a 2 × 2
contingency table (vassarstats.net/tbl2x2.html). Distribu-
tion normality for all continuous variables was assessed
per group by visual inspection of the data (shape and sym-
metry of distribution, outliers, P-P plot) and by Shapiro-
Wilk’s W-test, performed with Statistica, v 6 (StatSoft Inc.,
Tulsa, USA). The effect of cryopreservation was assessed
by comparing Treg frequencies and phenotype of the
same subjects before and after cryopreservation with
paired samples T test. Since the distribution of several var-
iables was typically skewed, we used a nonparametric re-
sampling procedure with 5,000 replications obtained from
the complete study sample for all variables and tests ap-
plied. Descriptive statistics and effect sizes (Cohen’s d)
with respective confidence intervals (CIs) were calculated
from the original dataset using bootstrap (resampling with
replacement) methods. Statistical inferences were verified
by randomization (resampling without replacement) test.
All sampling and computation was programmed using ex-
tended Resampling Stats language and run by Statistics
101, v 2.8 resampling statistics software (http://www.
statistics101.net). Results are presented as means (an
Figure 1 Gating strategy for identification of Tregs populations. Upon gating on CD3+CD4+ cells (A) a small percentage of cells with the
highest expression of CD25 was gated (B) among these CD25hi cells two distinct populations according to expression of FOXP3 and CD127
markers were visible (C). Tregs were identified as FOXP3+CD127lo/- subpopulation and divided into four subpopulations according to expression
of HLA-DR and CD127 (D).
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samples) ± SD of the sampling distribution (the estimate
of the sample SE) and effect sizes (ES, Cohen’s d) with
associated 95% confidence intervals (CI). Two-tailed
p-values were obtained as a proportion of the sampling
distribution of absolute differences between 5,000 ran-
domized group means (test statistic of interest) that are at
least as extreme as the difference between original groups
mean. Psychometric test scores (four LASC variables, one
BDI and one STAI-S variable) and phenotype variables




As shown in Table 1, the groups did not differ in respect
of age, marital status, smoking habit and alcohol con-
sumption. PTSD patients were slightly less educated,
and a substantial proportion of this group was retired or
unemployed. The patient group had higher scores in all
psychometric tests with higher frequency and intensity
of PTSD symptoms as well as higher levels of depression
and anxiety symptoms. Although there are reports of
low-grade inflammation determined by elevation of C-
reactive protein in PTSD patients [35,36], we found no
difference in CRP levels between groups (Table 1).
Lymphocyte phenotyping
We have calculated and presented results of both hy-
pothesis testing and the effect sizes of the difference in
phenotypic variables between PTSD patients and healthy
controls.
PTSD patients and healthy controls did not differ with
respect to absolute numbers of lymphocytes (PTSD:
2444,4 ± 144,7 cells/μl; controls: 2719,8 ± 115,6, p = 0.13,
ES = −0.11, 95% CI [−0.28, 0.03]), but PTSD patients
had significantly higher proportions of cytotoxic T cells(CD3+CD8+) (PTSD: 27.5 ± 1.94%, controls: 20.9 ± 1.52%,
p = 0.011; ES = 0.17 [0.05, 0.31]), B (CD3−CD19+) (PTSD:
5.7 ± 0.5%, controls: 2.7 ± 0.3%, p < 0.001; ES = 0.27 [0.18,
0.39] and NK cells (CD3−CD16+CD56+) (PTSD: 15.8 ±
2.5%, controls: 8.5 ± 0.7%, p < 0.01: ES = 0.15 [0.08, 0.22]).
Results obtained for total T (CD3+), helper T (CD3+CD4+)
cells, and their subpopulations, primarily Tregs subsets,
are shown in Figure 2. PTSD patients had a significantly
lower percentage of CD3+ (ES = −0.28 [−0.37, −0.19]) and
CD3+CD4+ (ES = −0.51 [−0.74, −0.33]) cells compared
to healthy controls. Upon gating on CD4+CD25hi cells
(Figure 1b), two populations were observed based on ex-
pression of FOXP3 and CD127 markers. We identified
Tregs as a distinct population of CD3+CD4+CD25+FOXP3+
CD127lo/- cells (Figure 1c) and further analyzed expression
of CD39 and HLA-DR markers on these cells (Figure 1d).
As shown in Figure 2, there was no difference in the
number of Tregs (ES = −0.01 [−0.07, 0.06]) but PTSD pa-
tients had a higher percentage of CD127−HLA-DR−
Tregs (ES = 0.17 [0.05, 0.29]) and a lower percentage
of CD127loHLA-DR+ Tregs (E = −0.17 [−0.32, −0.03]).
As shown in Table 2. Cryopreservation method had no ef-
fect on Treg numbers and phenotype. Measured frequen-
cies of Tregs in healthy controls and PTSD patients were
similar or higher than in previous reports based on whole
blood staining [26] further confirming no decrease in
FOXP3 levels caused by cryopreservation. No difference
in percentages of CD39+ Tregs (out of total Tregs) was
observed between study groups (E = −0.06 [−0.19, 0.06]).
In addition, we analyzed a subpopulation of recently acti-
vated non-regulatory helper T cells (CD4+CD25+FOXP3−
HLA-DR+) (Figure 2) and found no difference between
the study groups (E = −0.01 [−0.15, 0.09]).
These results suggest that PTSD has a moderate effect
(ES between 0.3 and 0.5) on total T and helper T cells and
a small effect (ES between 0.1 and 0.2) on CD127loHLA-
DR+ and CD127−HLA-DR− Tregs, but given that the
Table 1 Characteristics of participants
Variables PTSD patients (N = 21) Healthy controls (N = 23) p
Age, yearsa 45.9 ± 1,02 45.7 ± 1.64 0.949
Educationb 0.022
Elementary/high 21 (100) 17 (74)
University 0 (0) 6 (26)
Marital statusb 0.335
Married 18 (86) 22 (96)
Single/divorced 3 (14) 1 (4)
Work statusb < 0.001
Employed 1 (5) 21 (91)
Unemployed/retired 20 (95) 2 (9)
Tobacco useb 0.081
Yes 14 (67) 9 (39)
No 7 (33) 14 (61)
Alcohol useb 0.125
Yes 15 (71) 21 (91)
No 6 (29) 2 (9)
CRPa, mg/L 2.5 ± 0.50 2.3 ± 0.39 0.822
BDI scorea 30.3 ± 2.36 5.1 ± 1.18 < 0.001
LASC scoreare-experiencing 8.6 ± 0.47 1.3 ± 0.42 < 0.001
Avoidance 15.0 ± 1.05 4.4 ± 0.93 < 0.001
Arousal 22.5 ± 1.34 4.8 ± 1.00 < 0.001
17-item PTSD index 46.1 ± 2.63 10.4 ± 2.20 < 0.001
43-item full scale index 95.5 ± 5.48 36.0 ± 2.61 < 0.001
STAI-Statea, score 49.0 ± 1.04 36.0 ± 2.61 0.001
aData presented as mean (an estimate of population mean based on 5,000 bootstrap samples) ± SD of the sampling distribution (the estimate of the sample SE).
The associated two-tailed p-values are obtained as proportion of sampling distribution of absolute differences between 5,000 randomized group means that are
at least as extreme as the difference between original groups mean.
bData presented as n (%). The associated p-values are Fisher’s exact two-tailed probabilities.
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have important practical consequences.
Correlations and subgroup analyses
BDI, STAI-State, and LASC (3 clusters of PTSD symp-
toms, 17-item PTSD index, 43-item full scale indeks)
scores were correlated with phenotype variables in PTSD
patients. Out of 54 correlations performed between pheno-
type variables and psychometric test scores, only two
were statistically significant (without corrections for
multiple comparisons) – 1) BDI vs. CD127−HLA-DR−
(Spearman R = −0.44, p = 0.045), and 2) LASC arousal
vs. CD127loHLA-DR−(R = 0.46, p = 0.033).
We have also compared all phenotype variables be-
tween patients who were taking SSRIs (n = 12), benzo-
diazepines (n = 15), or antipsychotics (n = 8) and those
who were not using medication. The differences were
tested using the same nonparametric resampling pro-
cedure as described in Statistical analyses section. All
p values were above significance level (>0.05).Discussion
Although PTSD patients did not have decreased per-
centage of Tregs as hypothesized, our study shows an al-
tered phenotype of Tregs in war veterans with PTSD.
They had a higher percentage of CD127−HLA-DR− Tregs
and a lower percentage of CD127loHLA-DR+ Tregs in
comparison to healthy controls, suggesting a less suppres-
sive phenotype that could increase susceptibility to auto-
immune diseases.
We also observed some changes in major lymphocyte
populations. The percentage of circulating T lympho-
cytes in PTSD patients was lower in comparison to
healthy controls, which has been previously reported in
men with a past history of PTSD [37]. However most
studies showed no differences [38] or even higher num-
bers of T cells [39]. We also found a decreased propor-
tion of circulating helper T cells as in previous studies
[37,40] in contrast to other studies that have found no
differences [41] or higher numbers of helper T cells [39].
These contradictory findings can be explained by the
Figure 2 Comparison of T cell subpopulations in PTSD patients and healthy controls. Populations specified by indentation, beside stated
markers, are characterized also by the first marker of all antecedent populations (e.g. full annotation for total Tregs, FoxP3+CD127lo/-,
is CD3+CD4+CD25+FoxP3+CD127lo/-, see also Figure 1). Values are means of 5,000 bootstrap samples means (a point estimate of population mean)
with SD of the sampling distribution (the estimate of the sample SE) in the parentheses. p-values are obtained as proportion of absolute differences
between 5,000 randomized group means that are at least as extreme as the difference between original groups mean. In addition, effect sizes (dots)
with associated 95% confidence intervals (horizontal bars) are depicted. *expressed as % of alymphocytes, bCD4 lymphocytes, and ctotal Tregs.
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tients and no conclusions on immune reactivity in PTSD
patients should be drawn based on the sheer numbers of
T cell populations. With this in mind our main goal was
to examine the proportion and differentiation markers
of Tregs in PTSD patients.
Only one previous study [26] examined Tregs in PTSD
patients and reported a 48% reduction of regulatory T
cells (CD4+CD25hi FOXP3+) in chronic PTSD. We did
not replicate the findings of this study as there was no
difference in peripheral Tregs between our PTSD group
and healthy controls. It is important to note that the
inclusion of CD127 marker in our analysis allowed us











CD127loHLA-DR− Tregs 35,8 34,8 0,77
CD127loHLA-DR+ Tregs 35,96 37,56 0,53
CD127−HLA-DR+ Tregs 20,54 20,8 0,91
CD127−HLA-DR− Tregs 7,67 6,77 0,36
The impact of the cryopreservation method was tested by measuring Treg
frequencies and phenotype in fresh and freeze/thawed PBMCs of a small
random sample (N = 5). Treg frequencies and phenotype of the same subjects
before and after cryopreservation were compared with paired samples T test
(data represented as group means). The results indicate no effect of
cryopreservation on Treg numbers and phenotype.activated T cells. Most of the common markers used to
characterize Tregs can also be expressed by activated non-
regulatory T cells. Human FOXP3 was found to be transi-
ently expressed in T cell receptor-stimulated CD4+CD25−
T cells that do not have regulatory properties [42]. CD127
is constitutively down-regulated on functional human
Tregs, while it is highly expressed on effector/memory T
cells although activated non-regulatory T cells have also
been shown to down-regulate CD127 upon activation
[43]. Thus we have identified the CD4+CD25hiFOXP3+
CD127lo/- subpopulation of T cells as the purest in Tregs
but we cannot claim that absolutely all activated non-
regulatory T cells were excluded from the analysis. Al-
though there was no difference in Treg levels, we found
that PTSD patients display a lower proportion of
CD127loHLA-DR+ Tregs and a higher proportion of
CD127−HLA-DR− Tregs. HLA-DR expression identi-
fies a functionally distinct population of terminally
differentiated human Tregs [11]. FOXP3 expression is
significantly higher in the HLA-DR+ Tregs and these cells
exhibit earlier kinetics of responder T cells (Tresp) sup-
pression than the HLA-DR− subset [10]. The most in-
teresting difference in the Tregs phenotype was the
percentage of CD127−HLA-DR− cells which was signifi-
cantly higher in PTSD patients (15%) than in healthy con-
trols (9.3%). These cells are non-mature Tregs [44] that
are less suppressive than HLA-DR expressing cells and
were found to be impaired in multiple sclerosis patients.
Thus it appears that PTSD patients might exhibit a less
suppressive phenotype of peripheral Tregs although fur-
ther ex vivo analysis of Tresp inhibition is needed to
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PTSD have produced conflicting results although there is
evidence for increased peripheral inflammation mani-
fested by increased levels of pro-inflammatory cytokines
(IL-1β, IL-6 and TNF-α) [24,25]. Since multiple mecha-
nisms operate in Treg-mediated suppression, there are
various ways through which altered Treg differenti-
ation may contribute to the observed immune changes in
PTSD. There are reports of both increased [26] and
decresed [45] ex vivo proliferation of polyclonaly stimu-
lated effector T cells in PTSD patients. Tregs suppress
proliferation of other CD4+ and CD8+ T cells when Treg
and responder populations are co-cultured and stimulated
with specific antigen or a polyclonal TCR stimulator [46].
Therefore, to further examine functional consequences of
the observed alterations in Treg phenotype, the distinct
Treg subpopulations need to be isolated and cocultured
with stimulated Tresp cells, which was beyond the scope
of this study. Tregs also produce various cytokines such as
IL-10, IL-4, IL-35 and IL-13 which are involved in the
suppression of the pro-inflammatory cytokine response
[46,47]. Additionally, Tregs can steer monocyte differenti-
ation toward alternatively activated macrophages with
strong anti-inflammatory potential [48]. Alterations in all
of these Treg mechanisms of suppression could potentially
contribute to the immunological abnormalities described
in PTSD.
Future studies should establish whether the observed
changes in the Treg phenotype are due to changes in
differentiation and distribution of thymically derived
FOXP3+ regulatory T cells (tTregs) or induction of per-
ipheral Tregs (pTregs). This is complicated by the lack
of specific markers that can distinguish tTregs from
pTregs [8]. Thymically derived Tregs were shown to be
able to convert to Th17 cells [49] in the presence of
IL-6. Since higher levels of IL-6 in PTSD patients have
been reported in several studies [24] Tregs conversion to
inflammatory Th17 cells is an additional possible mechan-
ism of immune dysregulation that needs to be further
studied. Glucocorticoids inhibit the ability of antigen pre-
senting cells to stimulate effector T lymphocytes and favor
Tregs cell induction [50]. In a previous study our group
has shown that lymphocytes isolated from PTSD patients
exhibited decreased intracellular glucocorticoid receptor
(GCR) levels compared with controls [51], thus signaling
through GCRs is a way that neuroendocrine alterations in
PTSD could affect Tregs differentiation and function. De-
fects of Tregs differentiation and function are likely in-
volved in chronic inflammation implicated in PTSD and
higher prevalence of autoimmune disorders observed in
PTSD patients.
One of the limitations of the study is that we didn’t ad-
minister The Clinician-Administered PTSD Scale (CAPS),
considered to be the “gold standard” in PTSD assessment[52]. Instead, a self-report scale (LASC) was used to assess
the level of PTSD symptoms. We must emphasize that
the PTSD group analyzed in this study consisted of
treatment-resistant patients who started their treatment
shortly after the war in Croatia. They were assessed on
multiple occasions (yearly) with numerous tests including
CAPS according to multimodal assessment principles
[53]. The severity of their condition was also reflected in
the high BDI scores (Table 1). One cannot exclude the
possibility that the observed differences in cellular pheno-
type might have been the result of the comorbid depres-
sion in PTSD patients. However, out of all correlations
performed between severity of depression symptoms (BDI
scores) and phenotype variables, we found only one sig-
nificant correlation - BDI scores negatively correlated with
percentages of CD127−HLA-DR− cells, i.e. patients with
higher levels of depression symptoms tended to have
lower percentages of Tregs with this phenotype. On the
other hand, this subpopulation was found to be more
prevalent in PTSD patients, indicating that PTSD, and not
depression, was the more likely basis of this difference.
Another shortcoming of the study is that due to ethical
considerations, the majority of patients were medicated at
the time of the study. Although additional analyses did
not reveal any significant associations of phenotype vari-
ables with the type of drug patients were using, this ques-
tion remains open since the group sizes were too small to
draw valid conclusions from these analyses.
Conclusions
There is ample evidence in the literature for systemic in-
flammation and deleterious health consequences in PTSD,
but the mechanisms of immune dysregulation in PTSD
are not well understood. Results of this study indicate that
altered differentiation of Tregs might be involved in the
disruption of immune homeostasis in chronic stress. Since
the prevalence of PTSD is fairly common in the general
population and very high in individuals exposed to severe
trauma, research on immune systems in PTSD is of great
importance for understanding the mechanisms of trauma-
related development of somatic disorders and developing
future therapeutic interventions.
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